golidocitinib,azd4205
dizal pharmaceuticals
['lymphoma', 'jackpot8', 'lymsm', 'golidocitinib', 'ptcl']
congress |#asco23| qingqing cai reports the primary results from jackpot8 phase ii trial evaluating golidocitinib in r/r ptcl. the orr was 44.3% with tumor responses observed across different subtypes. golidocitinib demonstrated an acceptable safety profile #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm